drugset / Trial / NCT00081822
Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia
Phase 1
Completed
23 enrolled
University of Alabama at Birmingham
Genzyme, a Sanofi Company · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the recommended phase II dose of clofarabine when administered in combination with standard dose Ara-C to older (\>=60 years of age) patients with newly diagnosed acute myeloid leukemia (AML).
Timeline
- Start
- 2004-01
- Primary completion
- 2009-04
- Completion
- 2011-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clofarabine | Other / unclassified | 15 mg/m2 | Intravenous |
| Subject | Clofarabine | Other / unclassified | 20 mg/m2 | Intravenous |
| Subject | Clofarabine | Other / unclassified | 22.5 mg/m2 | Intravenous |
| Subject | Clofarabine | Other / unclassified | 30 mg/m2 | Intravenous |
| Subject | Clofarabine | Other / unclassified | 40 mg/m2 | Intravenous |
| Subject | Cytarabine | Small molecule | 100 mg/m2 | Intravenous |